Journal: Redox Biology
Article Title: Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease
doi: 10.1016/j.redox.2021.102167
Figure Lengend Snippet: β5i interacts with PLK2 and participates in its degradation. (A, B) Endogenous interactions between β5i and PLK2 were determined in SH-SY5Y cells immunoprecipitated with anti-β5i or anti-PLK2 antibody and analyzed by Western blot to detect PLK2 and β5i protein levels. (C, D) SH-SY5Y cells were transfected with the indicated plasmids. The interactions between β5i and PLK2 were determined by immunoprecipitation with anti-HA or anti-Myc antibody and analyzed by Western blot with the indicated antibodies. (E, F) The mRNA levels of PLK2 in SH-SY5Y cells with β5i overexpression or β5i knockdown were determined by real-time PCR. (G, H) The ubiquitylation levels of PLK2 in SH-SY5Y cells with β5i overexpression or β5i knockdown were examined by in vitro ubiquitin conjugation assay. The protein levels of PLK2 in SH-SY5Y cells with β5i overexpression (I, J) or β5i knockdown (K, L) were determined by Western blot. The half-life of PLK2 was assesses in SH-SY5Y cells with β5i overexpression (M, N) or β5i knockdown (O, P) treated with 10 μg/mL CHX for the indicated time. * P < 0.05.
Article Snippet: To confirm the specificity of immunoproteasome activities, we analyzed proteolytic activities in the presence or absence of selective β1i inhibitor ML604440 (MCE, 500 nM) and β5i inhibitor ONX0914 (MCE, 500 nM), respectively.
Techniques: Immunoprecipitation, Western Blot, Transfection, Over Expression, Knockdown, Real-time Polymerase Chain Reaction, In Vitro, Ubiquitin Proteomics, Conjugation Assay